Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tidal Therapeutics

- PMLiVE

Sanofi unveils new corporate brand and logo

Sanofi Pasteur and Sanofi Genzyme will unite under the new brand image

- PMLiVE

Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results

The trial confirms the potential benefit of targeting inflammation in prurigo nodularis

- PMLiVE

BMS and Century Therapeutics agree on deal potentially worth over $3bn

The collaboration unites Century’s iPSC-derived allogeneic cell therapy line with BMS’s record in developing oncology drugs and cell therapies

- PMLiVE

Pfizer expands access to lipid nanoparticle technology in new agreement with Acuitas Therapeutics

Acuitas’ LNP technology is already used in the Pfizer/BioNTech COVID-19 vaccine, Comirnaty

- PMLiVE

Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies

The strategic research collaboration between the two companies aims to develop AI-driven pipeline of precision-engineered therapies

- PMLiVE

Sanofi to pay $1.2bn to acquire Amunix and its ‘stealth’ technology

Sanofi will acquire Amunix’s next-generation protein engineering tech that allows biologic drugs to circulate in ‘stealth’ mode, becoming active only in diseased tissues

- PMLiVE

Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn

Novartis is to pay $300m upfront to BeiGene in a multifaceted deal to enhance its oncology portfolio and expand coverage of the Chinese market

- PMLiVE

Sanofi/GSK vaccine boosts immune response

The vaccine boosted neutralising antibodies by 9 to 43-fold regardless of which vaccine was given as a primary course

- PMLiVE

Lilly and Foghorn sign oncology deal

Eli Lilly has teamed up with Foghorn Therapeutics to develop drugs that target the chromatin regulatory system using Foghorn's proprietary Gene Traffic Control platform

- PMLiVE

Sanofi to buy acne specialist Origimm

The acquisition brings Origimm’s ORI-001 vaccine candidate against acne vulgaris into Sanofi’s vaccine pipeline, building its strength in mRNA technology

regeneron headquarters

Regeneron signs $900m cancer and infectious disease deal with Nykode

The deal with Norwegian clinical-stage vaccine specialist Nykode (previously Vaccibody) includes an upfront payment of $30m and an equity investment of $20m plus additional payments

- PMLiVE

Gilead to pay $745m for three oncology programmes from Arcus Biosciences

The deal will enable Gilead to accelerate the development of candidate molecules and explore treatment combinations with long-term partner Arcus Biosciences

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links